Suppr超能文献

2014 年至 2021 年美国中西部地区肺炎支原体的大环内酯类耐药性。

Macrolide Resistance in Mycoplasma pneumoniae, Midwestern United States, 2014 to 2021.

机构信息

Division of Clinical Microbiology, Department of Laboratory Medicine and Pathology, Mayo Clinicgrid.66875.3a, Rochester, Minnesota, USA.

Department of Medicine, Division of Infectious Diseases, Mayo Clinicgrid.66875.3a, Rochester, Minnesota, USA.

出版信息

Antimicrob Agents Chemother. 2022 Apr 19;66(4):e0243221. doi: 10.1128/aac.02432-21. Epub 2022 Mar 21.

Abstract

The epidemiology of macrolide resistance in () in the United States is incompletely described. Using a PCR assay targeting common mutations associated with macrolide resistance in M. pneumoniae (23S rRNA gene, A2063G/A2064G), the frequency of macrolide resistance was estimated to be 10% based on analysis of 114 samples tested from January 2014 to September 2021 at Mayo Clinic Laboratories. Seasonality data showed the highest rates of M. pneumoniae infection in the fall/early winter.

摘要

在美国,()中大环内酯类耐药的流行病学情况描述并不完整。本研究采用针对肺炎支原体中常见大环内酯类耐药相关突变(23S rRNA 基因,A2063G/A2064G)的 PCR 检测方法,对 2014 年 1 月至 2021 年 9 月在 Mayo 诊所实验室检测的 114 份样本进行分析,估计大环内酯类耐药的频率为 10%。季节性数据显示,肺炎支原体感染的高发期在秋季/初冬。

相似文献

1
Macrolide Resistance in Mycoplasma pneumoniae, Midwestern United States, 2014 to 2021.
Antimicrob Agents Chemother. 2022 Apr 19;66(4):e0243221. doi: 10.1128/aac.02432-21. Epub 2022 Mar 21.
2
Macrolide-Resistant Mycoplasma pneumoniae in the United States as Determined from a National Surveillance Program.
J Clin Microbiol. 2019 Oct 23;57(11). doi: 10.1128/JCM.00968-19. Print 2019 Nov.
3
Antibiotic sensitivity of 40 Mycoplasma pneumoniae isolates and molecular analysis of macrolide-resistant isolates from Beijing, China.
Antimicrob Agents Chemother. 2012 Feb;56(2):1108-9. doi: 10.1128/AAC.05627-11. Epub 2011 Nov 21.
4
Allele-specific real-time PCR testing for minor macrolide-resistant Mycoplasma Pneumoniae.
BMC Infect Dis. 2019 Jul 12;19(1):616. doi: 10.1186/s12879-019-4228-4.
5
Detection of macrolide resistance in Mycoplasma pneumoniae by real-time PCR and high-resolution melt analysis.
Antimicrob Agents Chemother. 2008 Oct;52(10):3542-9. doi: 10.1128/AAC.00582-08. Epub 2008 Jul 21.
6
Evaluation of Lightmix Mycoplasma macrolide assay for detection of macrolide-resistant Mycoplasma pneumoniae in pneumonia patients.
Clin Microbiol Infect. 2019 Mar;25(3):383.e5-383.e7. doi: 10.1016/j.cmi.2018.10.006. Epub 2018 Oct 26.
7
Regional Differences in Prevalence of Macrolide Resistance among Pediatric Mycoplasma pneumoniae Infections in Hokkaido, Japan.
Jpn J Infect Dis. 2016 May 20;69(3):186-90. doi: 10.7883/yoken.JJID.2015.054. Epub 2015 Jul 10.

引用本文的文献

1
Efficacy and safety of doxycycline for severe Mycoplasma pneumoniae pneumonia in pediatric patients.
Clin Exp Med. 2025 Jul 22;25(1):259. doi: 10.1007/s10238-025-01793-x.
2
Recent Macrolide Resistance Pattern of Mycoplasma Pneumonia in the World: A Systematic Review and Meta-Analysis.
Iran J Public Health. 2025 Mar;54(3):530-541. doi: 10.18502/ijph.v54i3.18246.
3
Macrolide resistance in in adult patients.
Front Cell Infect Microbiol. 2025 Mar 4;15:1496521. doi: 10.3389/fcimb.2025.1496521. eCollection 2025.
4
Protective immunity induced by a novel P1 adhesin C-terminal anchored mRNA vaccine against infection in BALB/c mice.
Microbiol Spectr. 2025 Mar 4;13(3):e0214024. doi: 10.1128/spectrum.02140-24. Epub 2025 Jan 20.
5
The epidemic characteristics of infection among children in Anhui, China, 2015-2023.
Microbiol Spectr. 2024 Oct 3;12(10):e0065124. doi: 10.1128/spectrum.00651-24. Epub 2024 Sep 3.
6
Expert consensus on the diagnosis and treatment of macrolide-resistant Mycoplasma pneumoniae pneumonia in children.
World J Pediatr. 2024 Sep;20(9):901-914. doi: 10.1007/s12519-024-00831-0. Epub 2024 Aug 14.
7
miRNA, lncRNA and circRNA: targeted molecules with therapeutic promises in Mycoplasma pneumoniae infection.
Arch Microbiol. 2023 Jul 21;205(8):293. doi: 10.1007/s00203-023-03636-3.

本文引用的文献

1
Macrolide-Resistant Mycoplasma pneumoniae Infections in Children, Ohio, USA.
Emerg Infect Dis. 2021 Jun;27(6):1588-1597. doi: 10.3201/eid2706.203206.
2
Macrolide-Resistant Mycoplasma pneumoniae in the United States as Determined from a National Surveillance Program.
J Clin Microbiol. 2019 Oct 23;57(11). doi: 10.1128/JCM.00968-19. Print 2019 Nov.
3
Mycoplasma pneumoniae from the Respiratory Tract and Beyond.
Clin Microbiol Rev. 2017 Jul;30(3):747-809. doi: 10.1128/CMR.00114-16.
4
Mycoplasma pneumoniae: Current Knowledge on Nucleic Acid Amplification Techniques and Serological Diagnostics.
Front Microbiol. 2016 Mar 31;7:448. doi: 10.3389/fmicb.2016.00448. eCollection 2016.
5
The Evolution of Advanced Molecular Diagnostics for the Detection and Characterization of Mycoplasma pneumoniae.
Front Microbiol. 2016 Mar 8;7:232. doi: 10.3389/fmicb.2016.00232. eCollection 2016.
6
New insights in the outbreak pattern of Mycoplasma pneumoniae.
Int J Med Microbiol. 2015 Oct;305(7):705-8. doi: 10.1016/j.ijmm.2015.08.021. Epub 2015 Aug 22.
7
Real-time PCR detection of Mycoplasma pneumoniae in respiratory specimens.
Diagn Microbiol Infect Dis. 2013 Nov;77(3):202-5. doi: 10.1016/j.diagmicrobio.2013.07.016. Epub 2013 Sep 14.
9
Impact of weather factors on Mycoplasma pneumoniae pneumonia.
Thorax. 2009 Jun;64(6):507-11. doi: 10.1136/thx.2008.111237. Epub 2009 Mar 23.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验